Related Experiment Videos
[Angiotensin II receptor antagonists: different or equivalent?]
1Service de Médecine interne et HTA, Hôpital Cardiologique, CHRU de Lille, F59037 Lille. cmouniervehier@chru-lille.fr
Presse Medicale (Paris, France : 1983)
|July 27, 2001
Summary
Angiotensin II receptor antagonists (ARA-II) are effective antihypertensive drugs with good tolerance. Comparative studies show clinical differences between ARA-II, impacting treatment strategies for cardiovascular risk reduction.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
Context:
- Angiotensin II receptor antagonists (ARA-II) represent a novel class of antihypertensive medications.
- Their mechanism of action is comparable to converting enzyme inhibitors (CEI).
- ARA-II exhibit favorable clinical and biological tolerance, similar to placebo.
Purpose:
- To evaluate the antihypertensive efficacy and clinical differences among various Angiotensin II receptor antagonists (ARA-II).
- To assess the impact of these comparative studies on clinical practice and cardiovascular risk management.
Summary:
- Early meta-analyses suggested equipotent blood pressure-lowering effects of ARA-II, but methodological flaws limited conclusions.
- Subsequent multicenter, randomized double-blind studies have demonstrated clinically significant differences between specific ARA-II at standard dosages.
- These findings are crucial for optimizing long-term blood pressure control and reducing cardiovascular complications.
Impact:
- Clinical practice is influenced by studies demonstrating differences in ARA-II efficacy and tolerance.
- Optimal blood pressure reduction, tolerance, and patient compliance are key to reducing cardiovascular risk.
- Upcoming large-scale studies on ARA-II morbidity and mortality will further define their role in therapeutic strategies.